Clinical Trials
22 trialsSURF
Centre Hospitalier Universitaire de Besancon
Style
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
SuAx
Instituto do Cancer do Estado de São Paulo
SUNLAND
GERCOR - Multidisciplinary Oncology Cooperative Group
Combining Sunitinib, Temozolomide and Radiation to Treat Patients Diagnosed With Glioblastoma
McGill University Health Centre/Research Institute of the McGill University Health Centre
Randomized Study of Doxorubicin and Cyclophosphamide With or Without Intermittent Sunitinib in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer Patients With Measurable Primary Breast Tumor
National University Hospital, Singapore
Docetaxel With or Without Low-dose, Short Course Sunitinib in Refractory Solid Tumors
National University Hospital, Singapore
Dose-dense Doxorubicin/Cyclophosphamide With Intermittent Low-dose Sunitinib in Breast Cancer Patients
National University Hospital, Singapore
A Phase II Trila of Sunitinib Schedule 4/2 vs. Shedule 2/1 as First Line Therapy in Metastatic Renal Cell Carcinoma.
Peking University Cancer Hospital & Institute
Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma
National Cancer Institute (NCI)
Sunitinib Before and After Surgery in Treating Patients With Stage IV Kidney Cancer
National Cancer Institute (NCI)
Sunitinib Before or After Surgery in Treating Patients With Metastatic Kidney Cancer
National Cancer Institute (NCI)
Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Urinary Tract Cancer
National Cancer Institute (NCI)
Sequential Use of Low-dose Sunitinib With Chemotherapy in Advanced NSCLC After Failure of Conventional Regimen
ChineseAMS
SMAT
Association of Urologic Oncology (AUO)
SMART
AHS Cancer Control Alberta
Neoadjuvant Sunitinib Treatment for Metastatic Clear Cell Renal Cell Carcinoma (RCC)
Korean Urological Oncology Society
Trial Of Sunitinib In Advanced Non-Clear Cell Type Renal Cell Carcinoma
Asan Medical Center
Sunitinib as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
Third Military Medical University
SURGE01-07
Medical University Innsbruck
Biomarker Study for Sunitinib and Docetaxel in Prostate Cancer
Medical University of Vienna
Salvage Therapy With Sunitinib,Docetaxel and Platinum on Metastatic or Unresectable Non Small Cell Lung Cancer
Taipei Medical University Hospital